FogPharma: $145 Million Raised To Discover And Develop Helicon Therapeutics
By Amit Chowdhry ● Mar 4, 2024
FogPharma - a clinical-stage biopharmaceutical company dedicated to delivering a new class of therapies that go beyond the limits of currently available medicines using its Helicon peptide platform - announced the successful closing of a $145 million Series E financing round. And the funding was led by Nextech Invest with participation from other new investors including RA Capital Management, Rock Springs Capital, General Catalyst, Marshall Wace, Samsara Biocapital, Foresite Capital, Symbiosis, Catalio Capital Management, Sixty Degree Capital and former chairman and CEO of Johnson & Johnson, Alex Gorsky.